Flatiron Health renews NCCN real-world oncology data collaboration through 2028, deploys Flatiron Telescope

The curation and tooling work sits with Flatiron: it structures de-identified oncology EHR data from NCCN academic members into longitudinal records spanning more than 6 million patient journeys, and layers Flatiron Telescope - a multi-agent natural-language analytics engine first launched May 2026 - on top for member researchers to query.

What makes the substrate commercially valuable is Flatiron's curation of unstructured EHR fields into regulatory-grade longitudinal records with biomarker depth - the same asset Roche paid $1.9bn for in 2018. Within this specific renewal there is no external paying buyer, so no payer-decision is named; the research NCCN members pursue (patterns of care, predictive biomarkers, disparities, comparative effectiveness) is academic rather than a purchased decision.

De-identified patient data from NCCN academic centers crosses into Flatiron's curated repository; access to that repository and to the Telescope query layer crosses back to NCCN member researchers under the renewed agreement through 2028. The underlying curation engine and the broader cross-institutional RWE substrate Flatiron sells to pharma are not transferred.

Not determinable from the public release: the renewal does not disclose whether money changes hands in either direction, so whether either party is leaving value on the table in this specific agreement cannot be read from the source.